Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 420-428

  Aggarwal, C ^a   Meropol, N J ^b   Punt, C J ^c   Iannotti, N ^d   Saidman, B H ^e   Sabbath, K D ^f   Gabrail, N Y ^g   Picus, J ^h   Morse, M A ⁱ   Mitchell, E ^j   Miller, M C ^k   Cohen, S J ^l  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d Hematology Oncology Associates   (United States)

^e Medical Oncology Associates   (United States)

^f Medical Oncology and Hematology   (United States)

^g Union Hospital   (United States)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j THOMAS JEFFERSON UNIVERSITY   (United States)

^k Veridex LLC   (United States)

^l FOX CHASE CANCER CENTER   (United States)

more..

Author keywords

CEA; Circulating tumor cells; Colorectal cancer

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL COUNT; CIRCULATING TUMOR CELL; COLORECTAL CANCER; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 84873817306     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds336     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics. CA Cancer J Clin 2010; 60: 277-300.
2. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965; 122: 467-481.
3. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439-62.
4. Boucher D, Cournoyer D, Stanners CP et al. Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue. Cancer Res 1989; 49: 847-852.
5. Wiggers T, Arends JW, Volovics A. Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum 1988; 31: 33-41.
6. Wolmark N, Fisher B, Wieand HS et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 1984; 199: 375-382.
7. Bhattacharjya S, Aggarwal R, Davidson BR. Intensive follow-up after liver resection for colorectal liver metastases: results of combined serial tumour marker estimations and computed tomography of the chest and abdomen-a prospective study. Br J Cancer 2006; 95: 21-26.
8. Zeng Z, Cohen AM, Urmacher C. Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in node-positive colon cancer patients. Dis Colon Rectum 1993; 36: 1063-1068.
9. Petrioli R, Licchetta A, Roviello G et al. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatinbased chemotherapy and bevacizumab. Cancer Invest 2012; 30: 65-71.
10. Aldulaymi B, Bystrom P, Berglund A et al. High plasma TIMP-1 and serum CEA levels during combination chemotherapy for metastatic colorectal cancer are significantly associated with poor outcome. Oncology 2010; 79: 144-149.
11. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127: 679-695.
12. Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-6904.
13. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
14. Cohen SJ, Punt CJ, Iannotti N et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 3213-3221.
15. Tol J, Koopman M, Miller MC et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 2010; 21: 1006-1012.
16. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-6309.
17. Wanebo HJ, Rao B, Pinsky CM et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978; 299: 448-451.
18. Grem J. The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Curr Opin Oncol 1997; 9: 380-387.
19. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318; discussion 318-321.
20. Nordlinger B, Guiguet M, Vaillant JC et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77: 1254-1262.
21. National Comprehensive Cancer Network. Guidelines for management of colon cancer, http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#colon (15 March 2012, date last accessed).
22. Reiter W, Stieber P, Reuter C et al. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 2000; 20: 5195-5198.
23. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676.
24. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572.
25. Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27: 5727-5733.
26. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006; 24: 394-400.
27. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-377.
28. Nagrath S, Sequist LV, Maheswaran S et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450: 1235-1239.
29. Sequist LV, Nagrath S, Toner M et al. The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol 2009; 4: 281-283.